Re: The UK-based company thatís striving to overcome the limitations of T cell receptor innovation
I greatly appreciate your statements of the lead that Rosenberg and Deniger have set up for Alaunos -- the very essence of success -- a comprehensive, automated interrogation and "capture" of each patient's neoantigen profiles.
I agree that elevated positive measurement of the "living drug" in the first metastatic cancer patient over several weeks should gain attention. In tandem with scans in September, there should be a wake-up. After all, first or millionth -- the blueprint's design process is the same ... (against an unmet need!). Thanks.